BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …

Objective. The long-term survival of renal cell cancer (RCC) patients is not reported in the
recent literature. This study evaluated the significance of known clinical prognostic factors …

Methodology. Since the start in 2005 virtually all patients with newly diagnosed renal cell
carcinoma (RCC) in Sweden are reported to the National Swedish Kidney Cancer Register …

Purpose Renal cell carcinoma (RCC) is a very heterogeneous disease with widely varying
prognosis. An accurate knowledge of the individual risk of disease progression and mortality …

Objectives To clarify treatment patterns and outcomes for patients with unresectable or
metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods A …

Objective. Tumour characteristics, preoperative work-up and surgical treatment in patients
diagnosed with renal cell carcinoma (RCC) between 2005 and 2010, and changes over time …

Renal cell carcinoma (RCC) accounts for 2% of all new cancer cases worldwide. Staging
systems for RCC are a valuable tool for guiding patient selection for the various treatment …

Objectives: To identify independent predictors of cause-specific survival in patients affected
by renal cell carcinoma (RCC). Material and Methods: We evaluated retrospectively 675 …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Background: The most important prognostic factors for survival in patients with metastatic
renal cell carcinoma (mRCC) were evaluated in the era of cytokine therapy, and only …